“…Patients are currently risk-stratified as average or high risk depending on factors such as age, extent of resection, and presence of metastases. Several series reporting around 30-48 patients [1,7,10,13,17,28,30] and one reporting 156 patients [5] were published in the last 2 decades evaluating adult medulloblastoma. While postoperative craniospinal irradiation is a well-established standard, the value of adjuvant chemotherapy has not been clearly defined in adults in contrast to pediatric patients [34].…”